Which has better earnings & valuation, NAVB or SCPS?

Scopus BioPharma has lower revenue, but higher earnings than Navidea Biopharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is NAVB or SCPS more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Scopus BioPharma N/A N/A N/A

Is NAVB or CLVR more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Clever Leaves N/A N/A N/A

Is NAVB or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Trevena N/A N/A -119.55%

Which has preferable earnings & valuation, NAVB or GNCA?

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A

Is NAVB or GNCA more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Genocea Biosciences N/A -182.88% -62.76%

Is PXMD or NAVB more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Navidea Biopharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals (NAVB) Competitors

Compare

NAVB vs. SCPS, CLVR, TRVN, GNCA, and PXMD

Should you buy Navidea Biopharmaceuticals stock or one of its competitors? MarketBeat compares Navidea Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Navidea Biopharmaceuticals include Scopus BioPharma (SCPS), Clever Leaves (CLVR), Trevena (TRVN), Genocea Biosciences (GNCA), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Navidea Biopharmaceuticals (NYSE:NAVB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Scopus BioPharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Scopus BioPharma	N/A	N/A	N/A

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scopus BioPharma has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Clever Leaves?

Navidea Biopharmaceuticals (NYSE:NAVB) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Clever Leaves. Clever Leaves is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Clever Leaves	Neutral

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, indicating that its share price is 381,513% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Clever Leaves	N/A	N/A	N/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Clever Leaves beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Trevena?

Navidea Biopharmaceuticals (NYSE:NAVB) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Trevena	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Trevena has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Trevena on 5 of the 8 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Genocea Biosciences?

Navidea Biopharmaceuticals (NYSE:NAVB) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Genocea Biosciences	Neutral

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Genocea Biosciences	N/A	-182.88%	-62.76%

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Navidea Biopharmaceuticals	Neutral

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Navidea Biopharmaceuticals	N/A	N/A	N/A

Navidea Biopharmaceuticals has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Summary

Navidea Biopharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAVB vs. The Competition

Export

Metric	Navidea Biopharmaceuticals	Diagnostic substances Industry	Medical Sector	NYSE Exchange
Market Cap	$10K	$22.68M	$6.87B	$23.47B
Dividend Yield	N/A	N/A	2.67%	4.20%
P/E Ratio	0.00	N/A	27.14	30.75
Price / Sales	N/A	0.02	517.06	166.31
Price / Cash	N/A	N/A	50.54	31.69
Price / Book	N/A	N/A	10.28	4.73
Net Income	-$15.18M	-$6.86M	$3.60B	$1.07B

Navidea Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+66.7%	$21K	N/A	N/A	9
CLVR Clever Leaves	N/A	$0.01 flat	N/A	+3,250.0%	$18K	$17.42M	N/A	560
TRVN Trevena	N/A	$0.01 flat	N/A	-98.8%	$11K	$443K	N/A	40	Gap Up
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NAVB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Navidea Biopharmaceuticals (NAVB) Competitors

NAVB vs. SCPS, CLVR, TRVN, GNCA, and PXMD

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Summary

How does Navidea Biopharmaceuticals compare to Clever Leaves?

Summary

How does Navidea Biopharmaceuticals compare to Trevena?

Summary

How does Navidea Biopharmaceuticals compare to Genocea Biosciences?

Summary

How does Navidea Biopharmaceuticals compare to PaxMedica?

Summary

Media Sentiment Over Time

NAVB vs. The Competition

Navidea Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Navidea Biopharmaceuticals (NAVB) Competitors

NAVB vs. SCPS, CLVR, TRVN, GNCA, and PXMD

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Does the media prefer NAVB or SCPS?

Is NAVB or SCPS more profitable?

Which has more risk & volatility, NAVB or SCPS?

Do institutionals and insiders believe in NAVB or SCPS?

Which has better earnings & valuation, NAVB or SCPS?

Summary

How does Navidea Biopharmaceuticals compare to Clever Leaves?

Which has preferable earnings & valuation, NAVB or CLVR?

Does the media refer more to NAVB or CLVR?

Which has more volatility & risk, NAVB or CLVR?

Is NAVB or CLVR more profitable?

Do institutionals and insiders hold more shares of NAVB or CLVR?

Summary

How does Navidea Biopharmaceuticals compare to Trevena?

Which has better earnings & valuation, NAVB or TRVN?

Does the media prefer NAVB or TRVN?

Is NAVB or TRVN more profitable?

Do institutionals & insiders hold more shares of NAVB or TRVN?

Which has more risk & volatility, NAVB or TRVN?

Summary

How does Navidea Biopharmaceuticals compare to Genocea Biosciences?

Which has preferable earnings & valuation, NAVB or GNCA?

Do institutionals & insiders believe in NAVB or GNCA?

Does the media refer more to NAVB or GNCA?

Which has more risk and volatility, NAVB or GNCA?

Is NAVB or GNCA more profitable?

Summary

How does Navidea Biopharmaceuticals compare to PaxMedica?

Do institutionals and insiders believe in PXMD or NAVB?

Does the media refer more to PXMD or NAVB?

Which has more risk & volatility, PXMD or NAVB?

Is PXMD or NAVB more profitable?

Which has stronger valuation & earnings, PXMD or NAVB?

Summary

Media Sentiment Over Time

NAVB vs. The Competition

Navidea Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools